HPLC · CoA
What Is the BPC-157 Half-Life, and How Do Other Peptides Compare?
Explainer · 9 min read · Updated 30 September 2026
The BPC-157 half-life reported in the most detailed pharmacokinetic study is about 15 minutes in rat plasma after intravenous administration, with elimination under 30 minutes across every route tested in rats and beagle dogs (Frontiers in Pharmacology, 2022). That figure describes clearance from the circulation of an animal model. It does not describe how long a sealed lyophilised vial or a reconstituted solution remains intact, which depends on temperature, moisture and handling. Sourced figures for TB-500, AOD-9604, GHRP-2 and DSIP follow in the reference table.
What Does Half-Life Mean for a Research Peptide?
Half-life is the time required for half of a starting quantity of a compound to be removed or degraded. After one half-life, half the material remains; after two, one quarter; after five, roughly one thirty-second. In peptide research the term covers two distinct measurements, and they must be recorded separately.
- **Plasma or elimination half-life:** the rate at which a compound is cleared from circulation in a living model, measured by sampling blood at timed intervals after administration.
- **Stability half-life:** the rate at which the intact peptide degrades in a vial, a buffer or an incubated serum sample, with no living system involved.
A peptide can be cleared from rat plasma within minutes and still remain stable for years as a dry powder held at minus 20 degrees C. Both statements are correct at once.
Why Do Small Linear Peptides Clear So Quickly?
Small linear peptides clear quickly because blood and tissue contain peptidases that cleave peptide bonds, and because molecules far smaller than albumin pass through renal filtration. Chains built from natural L-amino acids are the easiest substrates. Medicinal chemists extend circulation in a few established ways: D-amino acid or unnatural residue substitution, terminal capping, and conjugation of a fatty acid or reactive linker that binds serum albumin. CJC-1295 with DAC and cagrilintide rely on the albumin principle, so their circulation is measured in days rather than minutes.
Reported Half-Lives at a Glance
Each figure is tied to its study and model. Where no traceable figure exists, the table states that instead of repeating an unsourced number.
| Compound | Length and mass | Reported half-life | Model and source |
|---|---|---|---|
| BPC-157 | 15 residues, about 1,419 Da | about 15 minutes after intravenous administration; under 30 minutes across routes | rats and beagle dogs, Frontiers in Pharmacology, 2022 |
| Thymosin beta 4 (TB-500) | 43 residues, about 4,963 Da | intravenous pharmacokinetics characterised in a phase 1 study; no widely cited animal figure | Annals of the New York Academy of Sciences, 2010 |
| AOD-9604 | 16 residues, about 1,815 Da | no peer-reviewed plasma figure widely cited | fragment work in obese Zucker rats, Hormone Research, 2000 |
| GHRP-2 | 6 residues, about 818 Da | tens of minutes, largely inferred from the timing of the growth hormone response | pharmacology literature; direct plasma assays are limited |
| DSIP | 9 residues, about 849 Da | about 15 minutes in plasma incubated in vitro | Peptides, 1987 |
| CJC-1295 with DAC | GRF 1-29 analogue plus linker | several days, from albumin binding | rat work, Endocrinology, 2005 |
How Was the BPC-157 Half-Life Measured in Rats and Dogs?
The BPC-157 half-life was measured in a full pharmacokinetic, distribution and excretion programme run in rats and beagle dogs and reported by Frontiers in Pharmacology (2022). BPC-157 is a 15 residue synthetic sequence, GEPPPGKPADDAGLV, derived from a protein fragment first isolated from gastric juice, and before that study its circulation time was usually quoted without a source. Rats received a single intravenous administration and single intramuscular administrations at three increasing amounts; dogs were studied the same way, with a repeated intramuscular arm added.
Clearance of the intact peptide was rapid, with elimination half-life under 30 minutes in every arm. Exposure increased in proportion to the amount given, which the authors described as linear pharmacokinetics. Intramuscular bioavailability differed sharply between species, roughly one sixth in rats and close to one half in dogs. A tritium-labelled form traced excretion mainly through urine and bile, with the peptide broken down into smaller fragments and free amino acids.
For time-course study design, a clearance of around 15 minutes requires tight sampling windows. Points at 5, 10, 15, 30 and 60 minutes capture most of the decay curve, while a single sample at two hours would miss it entirely.
What Is the Half-Life of Thymosin Beta 4 (TB-500)?
Thymosin beta 4 has no single animal plasma half-life that is cited consistently, although its intravenous pharmacokinetics were characterised in a phase 1 study published in the Annals of the New York Academy of Sciences in 2010. The protein has 43 amino acids with an acetylated first residue and is one of the most abundant peptides inside cells, particularly platelets and white cells. That abundance means the background plasma level is never zero, which complicates any clearance measurement.
Nomenclature adds a second variable. TB-500 is a market name applied by some suppliers to the full 43 residue chain and by others to a short fragment around the actin-binding motif LKKTETQ. A fragment of a few residues and a protein of nearly 5,000 daltons will not share a half-life, so the certificate of analysis should be checked for the exact form in the vial. The N-terminal tetrapeptide Ac-SDKP, released when the protein is cleaved, is studied separately and has its own clearance profile.
What Is the Half-Life of AOD-9604?
AOD-9604 has no peer-reviewed plasma half-life that is cited consistently across the literature. AOD-9604 is built on the growth hormone sequence spanning positions 177 to 191, with one tyrosine added at the N-terminus, giving 16 residues, and it retains the internal disulfide bridge of the parent sequence. Its early metabolic work, published in Hormone Research in 2000, used obese Zucker rats and examined lipid metabolism rather than pharmacokinetics. Precise figures quoted without a citation should be treated with caution. Its size and linear structure suggest clearance similar to other small peptides, but that is an inference, not a measurement.
What Is the Half-Life of GHRP-2?
Published estimates place the GHRP-2 half-life in the tens of minutes, though many are inferred from the rise and fall of growth hormone rather than from a direct assay of the peptide. GHRP-2, also called pralmorelin, is a hexapeptide with the sequence D-Ala, D-2-Nal, Ala, Trp, D-Phe, Lys and an amidated C-terminus. Its three D-configured residues give it far greater peptidase resistance than a natural sequence of the same length. An inferred value is weaker evidence than a direct plasma assay, so the method behind each figure should be recorded before values are compared.
How Fast Does DSIP Break Down in Plasma?
DSIP breaks down with a half-life of about 15 minutes when incubated in plasma in vitro, according to a 1987 study in Peptides. Delta sleep-inducing peptide is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, with no protective modifications. The main route of degradation is an aminopeptidase-like activity that removes the N-terminal tryptophan and then the adjacent alanine. The same study reported aggregation in serum, which affects how assay results are interpreted. DSIP is a standard example of an unmodified peptide that is stable as a lyophilised powder and fragile in biological fluid.
How Does In-Vitro Stability Differ From Plasma Half-Life?
In-vitro stability is governed by water, temperature, light, oxygen and handling, whereas plasma half-life is governed by enzymes and renal clearance in a living system. A freeze-dried cake contains almost no free water, so hydrolysis and enzymatic activity barely proceed. Degradation begins in earnest once the peptide is reconstituted.
| Storage state | Standard laboratory practice | Main limit on stability |
|---|---|---|
| Lyophilised, sealed, minus 20 degrees C | long-term holding, months to years | moisture entering the vial |
| Lyophilised, sealed, 2 to 8 degrees C | short-term holding before use | slow oxidation of sensitive residues |
| Reconstituted in bacteriostatic water, 2 to 8 degrees C | working stock, used within 28 days of first puncture | hydrolysis, microbial ingress through the septum |
| Reconstituted, room temperature | avoided beyond the working session | faster hydrolysis and aggregation |
| Repeated freeze and thaw | avoided; split into single-use aliquots instead | ice crystal stress, aggregation |
The 28 day window follows the in-use convention for multi-use vials preserved with benzyl alcohol, which is why bacteriostatic water suits any working stock that will be sampled repeatedly. Our release testing for each lot combines an HPLC purity result of 98% or higher with a mass spectrometry identity check, with a certificate issued per lot, so the starting material is characterised before stability work begins.
How Should Half-Life Figures Be Used in Research Planning?
Half-life figures should be used to set sampling schedules and washout intervals, always with the species, route and source recorded beside each value. The following practices keep the data comparable.
- Record species, route and source next to every figure, because a rat intravenous value and a dog intramuscular value are not interchangeable.
- Build sampling schedules around the half-life, since most of the decay occurs within three to four half-lives.
- Allow about five half-lives between conditions where washout matters.
- Never apply a plasma figure to vial storage, or a storage figure to plasma.
- Note whether a value came from a direct peptide assay or was inferred from a downstream hormone response.
Our recommendation: keep plasma half-life and bench stability in two separate columns of the laboratory record, each with its source. Every compound discussed here, along with the rest of our recovery research peptides, is supplied with a lot-matched certificate of analysis to support that record.
Questions about BPC-157 half-life
Sources
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022.
- Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987.
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research. 2000.
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.